Premium
Dimethylarginines as biomarkers for the kidney transplant management in methylmalonic aciduria
Author(s) -
AldámizEchevarria Luis,
Andrade Fernando,
Llarena Marta,
Heras Javier,
Couce María Luz
Publication year - 2015
Publication title -
nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 61
eISSN - 1440-1797
pISSN - 1320-5358
DOI - 10.1111/nep.12479
Subject(s) - medicine , asymmetric dimethylarginine , transplantation , methylmalonic acid , kidney disease , kidney , kidney transplantation , intensive care medicine , decompensation , gastroenterology , homocysteine , arginine , biochemistry , chemistry , amino acid
Methylmalonic aciduria ( MMA ) is an inborn error of metabolism associated with many complications despite treatment. Chronic renal failure is the most common problem, and patients may eventually require kidney transplant. Therefore, it is worth investigating whether living donor kidney transplant offers a better option than deceased kidney donors; and the value of novel vascular risk biomarkers in the assessment of transplanted MMA patients. We report a case of a 26‐year‐old man with MMA , who progressed to end‐stage renal disease and received kidney transplant from a heterozygous next‐of‐kin living donor at 20 years of age. Although post‐transplant urinary levels of methylmalonic acid decreased, this reduction was lower than previously reported for deceased donors. No episodes of metabolic decompensation were observed after transplantation. During his clinical progress, vascular complications appeared; and finally, pancreatitis was the cause of death. After kidney transplant, we evaluated novel vascular risk factors, such as asymmetric dimethylarginine ( ADMA ) and symmetric dimethylarginine ( SDMA ), which were used as early biomarkers of progression and metabolic management for this transplanted patient. This case report illustrates the disadvantage of transplantation with an allograft from a heterozygous living donor, and the utility of vascular risk biomarkers in renal transplant assessment.